Comparison of the clinical expression of patients with ankylosing spondylitis from Europe and Latin America.

M. Benegas, E. Muñoz-Gomariz, P. Font, R. Burgos-Vargas, J. Chaves, D. Palleiro, J. Maldonado Cocco, M. Gutiérrez, R. Sáenz, I. Steckmen, O. Rillo, J. Mulero, P. Sampaio-Barros, A. Barcelos, B. Vander Cruyssen, J. Vazquez-Mellado, E. Collantes, Respondia Group, Leon Verbruggen

Research output: Contribution to journalArticlepeer-review

37 Citations (Scopus)

Abstract

OBJECTIVE:

To compare the clinical, demographic, and serologic characteristics and the treatment of patients diagnosed with ankylosing spondylitis (AS) from Europe (EU) and Latin America (LA).

METHODS:

We included 3439 patients from national registries: the Spanish Registry of Spondyloarthritis (REGISPONSER), the Belgian registry (ASPECT), and the Latin American Registry of Spondyloarthropathies (RESPONDIA). We selected patients with diagnosis of AS who met the modified New York classification criteria. Demographic, clinical, disease activity, functional, and metrological measurement data were recorded. Current treatment was recorded. The population was classified into 2 groups: patients with disease duration <10 years and those with disease duration ? 10 years. A descriptive and comparative analysis of variables of both groups was carried out.

RESULTS:

There were 2356 patients in EU group and 1083 in LA group. Prevalence of HLA-B27 was 71% in LA group and 83% in EU group (p <0.001). We found a greater frequency of peripheral arthritis and enthesitis (p <0.001) in the LA population; prevalence of arthritis was 57% in LA and 42% in EU, and for enthesitis, 54% and 38%. Except for treatment with anti-tumor necrosis factor (anti-TNF), the use of nonsteroidal antiinflammatory drugs (NSAID), corticosteroids, and disease-modifying antirheumatic drugs (DMARD), and the association of anti-TNF and methotrexate use showed a significant difference (p <0.001) in the 2 populations.

CONCLUSION:

The principal differences in the clinical manifestations of patients with AS from EU and LA were the greater frequency of peripheral arthritis and enthesitis in LA group, the higher percentage of HLA-B27 in EU group, and the form of treatment, with a greater use of NSAID, steroids, and DMARD in the LA group.
Original languageEnglish
Pages (from-to)2315-2320
Number of pages6
JournalJ Rheumatol
Volume39
Issue numberDecember
Publication statusPublished - 2012

Keywords

  • ankylosing spondylitis
  • Europe
  • Latin America

Fingerprint

Dive into the research topics of 'Comparison of the clinical expression of patients with ankylosing spondylitis from Europe and Latin America.'. Together they form a unique fingerprint.

Cite this